Five-day Vidaza dosing shows efficacy
Azacitidine study shows five-day dosing schedule is efficacious
Canadian study in elderly finds glitazones increase heart risk
Glitazone study shows CV risk may be higher for elderly
Genetic test prior to carbamazepine recommended for Asians
Asians should receive genetic test prior to initiating carbamazepine
Drug Topics survey finds R.Ph.s approve of BTC class of drugs
Drug Topics poll: R.Ph.s favor BTC class of drugs
Consumers Union against OTC Mevacor
Consumers Union opposes OTC Mevacor
Analysis of PPI cardiovascular risk encouraging
FDA says long-term PPI use does not pose cardiovascular risk
US Script's RxDirect receives VIPPS accreditation from NABP
NABP awards US Script's RxDirect VIPPS Accreditation
PTCB mulling new plans for technicians
The Pharmacy Technician Certification Board is considering offering a new certification program in IV admixture as well as continuous testing
Orphan drug under study to be available to more patients
Gentium expands access to defibrotide under compassionate use basis
DEA suspends second Cardinal DC
The Drug Enforcement Administration has suspended the license at a second Cardinal Health distribution facility located in Lakeland, Fla.
Longs Drugs to open first walk-in medical clinic in Hawaii
Longs Drugs to open walk-in medical clinic in Hawaii
CRN calls for transparency in testing dietary supplements
CRN responds to Informed-Choice report calling for transparency in testing dietary supplements
SPECIAL(TY) DELIVERY
Pharmacy directors see pipeline chock full of specialty drugs and compounds.
New trials may cut clopidogrel use
A trio of late-breaking clinical trials could change standard drug treatment for patients undergoing percutaneous coronary intervention, or PCI.
Here's a 'smart' way to identify IV pumps
Company develops software to place barcodes on hospital's IV smart pumps, allowing it to track the pumps throughout the facility.
This breast cancer drug is first in new class of chemo agents
The FDA has approved Ixabepilone (Ixempra) as a monotherapy and in combination with capecitabine (Xeloda) for patients with metastic or locally advanced breast cancer.
Beneficiary participation in MTM services
While there still is a great deal of variation in the MTM programs for 2007, pharmacist involvement has increased relative to the degree of pharmacist involvement in 2006.
Many pharmacies not ready for DMEPOS accreditation
Pharmacies that sell DMEPOS supplies to Medicare patients face a variety of options for accreditation.
Survey finds employers give high marks to PBMs
Arxcel's prescription benefits survey for 2007 reveals the impact of and perceptions toward prescription benefits provided as a part of employee health benefits in corporate America.
CMS to set standard Medicare reimbursement rate for some cancer drugs
New Medicare rule cuts reimbursement for class of non-Hodgkins lymphoma treatments
Report: Networked medical sensors to aid millions of seniors by 2012
More than three million seniors will benefit from networked medical sensors at home in 2012.
HHS panel focuses on medical errors
Agency for Healthcare Research and Quality releases new tools to help reduce medical errors
White Paper out on managing Rx hazardous waste in hospitals
White paper focuses on managing hazardous pharmaceutical waste in hospitals
Two new guides summarize efficacy and safety of diabetes meds
New guides outline latest evidence on Type 2 diabetes medications
Latebreakers: New AHRQ report compares antirheumatics
A new report funded by AHRQ offers findings on which medications work better to treat rheumatoid arthritis
Latebreakers: FDA OK's OTC Zyrtec
FDA approves allergy treatment Zyrtec (cetirizine HCl) for over-the-counter use
Latebreakers: CMS proposes Medicare e-prescribing standard
The Centers for Medicare and Medicaid Services has proposed a rule that would create a new standard for electronic prescriptions for the Medicare Part D program.
Latebreakers: If Mevacor goes OTC, Glaxo will push it
GSK gets OTC marketing rights from Merck for Mevacor
Latebreakers: USP revises compounding standards to improve patient safety
Changes in compounding standards take effect on June 1, 2008
Latebreakers: Final DEA rule OKs multiple Schedule II Rxs
A final rule from the DEA allows doctors to give patients multiple prescriptions for up to a 90-day supply of Schedule II controlled substances.
